CN102813855B - Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof - Google Patents
Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof Download PDFInfo
- Publication number
- CN102813855B CN102813855B CN2012103343875A CN201210334387A CN102813855B CN 102813855 B CN102813855 B CN 102813855B CN 2012103343875 A CN2012103343875 A CN 2012103343875A CN 201210334387 A CN201210334387 A CN 201210334387A CN 102813855 B CN102813855 B CN 102813855B
- Authority
- CN
- China
- Prior art keywords
- radix
- chronic viral
- viral hepatitis
- hepatitis
- chinese herbal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese herbal preparation used for treating chronic viral hepatitis type b, comprising the following raw materials in percentage by weight: 4.5-10% of herba patriniae, 4.5-10% of coix seed, 4.5-5% of ginseng, 4.5-5% of white atractylodes rhizome, 4.5-5% of roasted milk vetch, 4.5-5% of eucommia bark, 9-10% of semen cuscutae, 1-2% of coptis chinensis, 2-3% of prepared pinellia ternate, 2-3% of dried tangerine or orange peel, 5-6% of white paeony root, 9-10% of prepared rehmannia root, 2.8-3.1% of salviae miltiorrhizae, 2.8-3.1% of safflower, 2.8-3.1% of peach kernel, 4-5% of liquorice, 2.8-3.1% of green tangerine peel, 6-6.5% of bupleurum, 4.5-5% of fingered citron, 9-10% of prepared turtle shell, 3-3.7% of poria cocos and 1.6-1.9% of rhizoma alismatis. The invention also provides a taking method of the Chinese herbal preparation. The Chinese herbal preparation disclosed by the invention has the advantages of good curative effect and no side effect, and the chronic viral hepatitis type b and a hepatitis B virus carrier can be fundamentally treated.
Description
Technical field
The invention belongs to a kind of Chinese medicine preparation, be specifically related to a kind of Chinese medicine preparation and instructions of taking for the treatment of the chronic viral hepatitis B disease.
Background technology
Hepatitis B, be called for short hepatitis B, is a kind of by caused disease after hepatitis B virus (HBV) infection body.Hepatitis B virus is a kind of Hepadna Virus, mainly is present in hepatocyte and damages hepatocyte, causes hepatocyte inflammation, necrosis, fibrosis.The chronic viral hepatitis B performance differs, if any HBV chronic carrier, chronic active hepatitis B, hbv-liver cirrhosis etc.
According to worldwide health organization, HBV was once infected in the whole world approximately 2,000,000,000 people, and wherein 3.5 hundred million people are chronic infection person, approximately had every year 1000000 people to die from HBV and infected and relevant disease.The survey showed that for prevalence of hepatitis B that China carried out in 2006 virus: China 1-59 year crowd hepatitis B virus carrying rate is 7.18%, below 5 years old, child's HBsAg carrying rate is only 0.96%, calculate accordingly, the existing Patients with Chronic HBV Infection of China is 9,300 ten thousand people approximately, wherein have the activeness hepatitis B patient that symptom need to be treated to be about more than 2,000 ten thousand.The annual direct economic loss that causes because of hepatitis B of China reaches 50,000,000,000 yuan.But so far chronic viral hepatitis B is still lacked desirable Therapeutic Method and medicine.Therefore how effectively to prevent and treat hepatitis B and be still the key subjects that 21 century will face and need solution.
Approximately have 1/3rd hepatic injury is repeatedly arranged in the B-type hepatitis patient, show as hepatitis B or the liver cirrhosis of activeness.Will inevitably cause organism immune response after hepatitis b virus infection, thereby produce different detection of plasma marks, think that at present the immunne response of the pathogenesis of hepatitis B and body is closely related, especially the cellullar immunologic response in body, when body's immunity low, during the situations such as not exclusively immunologic tolerance, or HBV gene mutation escape from immune removing, cause chronic hepatitis.Hepatitis B virus is mainly invaded hepatocyte, settle down and copy in hepatocyte, while therefore for hepatitis B patient, falling ill, main manifestations is abnormal liver function, hepatitis B also usually causes liver to be damaged outward, its reason is mainly caused by immune complex, can hyperamization final proof pathological changes as acute hepatitis b, be because immune complex deposit due to blood vessel wall and articular cavity synovial membrane and the activating complement, chronic hepatitis B is because circulating immune complex is deposited on blood vessel wall, cause the membranous glomerulonephritis nephrotic syndrome that occurs together, the clinical hepatorenal syndrome of crying.Cause quality of life to descend and heavy mental anguish for vast hepatitis B patient.
The clinical manifestation of chronic hepatitis B is: repeatedly occur weak, dizzy, detest oil, yellowish urine, uncomfortable liver area, sleep is not good enough, liver touch slightly greatly the pain, slight splenomegaly can be arranged.Or the clinical symptoms that obviously continues further appears, as poor appetite, abdominal distention, loose stool etc., companion's hepatic facies, liver palm, spider angioma, splenomegaly, ALT and (or) aspartate aminotransferase raises.Some cases symptom, sign lack as, liver function index is 1 or 2 mile abnormality only, but lab testing HBV-DNA quantitatively obviously raises, and shows that like this viral hepatitis is in active stage.
The overall goal for the treatment of of chronic is: long term inhibition HBV to greatest extent, alleviate hepatocyte inflammatory necrosis and hepatic fibrosis, delay and reduce the generation of Liver failure, liver cirrhosis, primary hepatocarcinoma and complication thereof, thereby make the life better quality and prolongation time-to-live.
At present, general Therapeutic Method mainly comprises following several:
1, interferon (comprising long-acting interferon PEG recently).Its clinical practice time is more of a specified duration, and abundant information, determined curative effect, short treating period can improve hepatocyte and learn index, but the desirable case of adaptation interferon therapy is less.Forbid in liver cirrhosis and lose compensatory person, untoward reaction is more, toleration is poor, also need drug administration by injection, clinical less use at present.
2, ucleosides.To draw the pyridine of miaow furan as representative.Can suppress rapidly virus replication.Be applicable to interferon taboo or the failed hepatitis B patient for the treatment of, oral administration, better tolerance, without obvious adverse reaction, medical treatment cost is relatively low.But Time of Administration is grown (more than 1-2), and some cases easily produces virus variation, and inappropriate drug withdrawal can cause Relapse rate or deterioration, therefore must strictly grasp indication and drug withdrawal indication.
3, gene therapy.Comprise agent interfering, cell suicide gene of antisense nucleotide, ribozyme, defective virus etc.Theoretically, this is the therapy that finally solves chronic viral hepatitis B.But due to the technical problem of complexity such as gene transfering efficiency and expression rate low, and the random integration of therapeutic gene in host genome, may activate proto-oncogene or deactivation antioncogene, cause the safety issues such as malignant change of cell, estimate still can not be used for clinical as conventional treatments within the long duration.In recent years, many new ucleosides medicines, as adefovir ester, because replacing the Lip river Wei, complying with bent western Horizon, the pyridine of gram force furan etc., untoward reaction is less, and is evident in efficacy, generally adopted by clinical at present.But very strong potential nephrotoxicity is also arranged, in case and its drug withdrawal, the phenomenon that hepatitis increases the weight of appears in patient possibly.
4, immunomodulator.Can reach the purpose of inhibition/removing hepatitis virus by the regulation and control body's immunity.Take thymosin Thymosinal (tal) as representative, the next day intramuscular injection 6 months, the suppression ratio of HBeAg and HBVDNA is about 41.2% and 45.3%.Have no adverse reaction, and prolong effect after having, can be used for the mixed infection case, with IFN, share and can improve late result.But complicated operation, expensive make the application be restricted.
5. Chinese medicine.For a long time, especially after the seventies, the report of application traditional Chinese medical herbal treatment chronic viral hepatitis B is increasing, and obtains curative effect.Its superiority shows and can obviously improve patient's symptom and quality of life, and can bring into play by multiple target effect protect the liver, immunomodulating, fibrosis and antiviral effect, essentially no untoward reaction, medical treatment cost is relatively low.But the multiformity for the treatment of rule, the reasons such as uncertainty of curative effect, making the reliability of traditional Chinese medical herbal treatment chronic viral hepatitis B and applying effectiveness still has limitation.Traditional Chinese Medicine Anti viral therapy method is a lot, comprises determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, immobilised compound and single Chinese herbal medicine; Objective evaluation, have his own strong points shortage respectively arranged; But, which kind of method no matter, must use definite, objectively curative effect is as foundation.Wherein, kurarinone and bicyclol are to have the novel formulation of anti-hepatitis virus in present clinical application method; Kurarinone (alkali) is to refine from Herba Sophorae alopecuroidis and obtain, verified its effective ingredient is that oxymatrine, clinical practice show to have function for protecting liver and reducing enzyme activity, liver function be can improve, hepatitis B virus duplication and effect of anti hepatic fibrosis suppressed, but the medication initial stage can make the transaminase raise, part patient is difficult to comply with, and medication haves much room for improvement; Bicyclol (hundred the match promises, Bicyc101) be China first have an anti-hepatitis new drug of class of independent intellectual property right.Relatively there is the enzyme of falling (ALT/AST) effect obviously with bifendate, certain anti-HBV effect is arranged, the advantage such as untoward reaction is less, it falls enzyme effective percentage 53%, HBeAg and HBV-DNA negative conversion rate are respectively 29% and 45.7%, but liver function loses compensatory person and be cautious use of, and still need and further explore.
In sum, several schemes of western medical treatment all can effectively suppress copying of hepatitis B virus at present, but can not thoroughly remove the hepatocyte inner virus, and several therapeutic schemes have narrow application range or take for a long time (more than 1-2) generation virus variation formation drug resistance, easily have a rebound after drug withdrawal and maybe may activate proto-oncogene or deactivation antioncogene, cause the serious problems such as malignant change of cell, and the expensive defect of popularizing that is difficult for.The present method of Chinese medicine all can be brought into play hepatoprotective, immunomodulating, fibrosis and antiviral effect by multiple target effect, essentially no untoward reaction, and medical treatment cost is relatively low.But the problems such as the polytropy of existence treatment rule, the uncertainty of curative effect and repeatability are poor.Therefore, no matter be Western medicine or Chinese medicine, various antiviral drugs have its advantages and disadvantages, and generally speaking, method is on the increase, and curative effect improves constantly, but there is no breakthrough progress; Comparatively speaking, the antiviral curative effect of Chinese medicine not yet can fully show its superiority, therefore there is the expert to propose viewpoint " who can stop/reverse hepatic fibrosis; who just can treat most hepatopathy ", " who can really suppress/remove hepatitis virus to inference, and who just can delay or stop generation and the development of hepatic fibrosis thus.Therefore, the Chinese medicine preparation of a kind of novel treatment chronic viral hepatitis B disease of research is the direction of those skilled in the art's effort always.
Summary of the invention
Based on this, the invention reside in the defect that overcomes prior art, a kind of Chinese medicine preparation for the treatment of the chronic viral hepatitis B disease is provided.
The present invention also provides a kind of instructions of taking of Chinese medicine preparation of above-mentioned treatment chronic viral hepatitis B disease.
For solving the first problem of above-mentioned proposition, its technical scheme is as follows:
a kind of Chinese medicine preparation for the treatment of the chronic viral hepatitis B disease, according to weight ratio, formed by following raw material, Herba Patriniae: 4.5-10%, Semen Coicis: 4.5-10%, Radix Ginseng: 4.5-5%, the Rhizoma Atractylodis Macrocephalae: 4.5-5%, Radix Astragali Preparata: 4.5-5%, the Cortex Eucommiae: 4.5-5%, Semen Cuscutae: 9-10%, Rhizoma Coptidis: 1-2%, Rhizoma Pinelliae Preparata 2-3%, Pericarpium Citri Reticulatae: 2-3%, the Radix Paeoniae Alba: 5-6%, Radix Rehmanniae Preparata: 9-10%, Radix Salviae Miltiorrhizae: 2.8-3.1%, Flos Carthami: 2.8-3.1%, Semen Persicae: 2.8-3.1%, Radix Glycyrrhizae: 4-5%, Pericarpium Citri Reticulatae Viride: 2.8-3.1%, Radix Bupleuri: 6-6.5%, Fructus Citri Sarcodactylis: 4.5-5%, Carapax Trionycis (processed): 9-10%, Poria: 3-3.7%, Rhizoma Alismatis: 1.6-1.9%.
Below further technical scheme is described:
Preferably, above-mentioned raw material is mixed after porphyrize is pulverized in oven dry and make the watered pill.
For solving the Second Problem of above-mentioned proposition, its technical scheme is as follows:
A kind of instructions of taking for the treatment of the Chinese medicine preparation of chronic viral hepatitis B disease, take oral method, and each serving using 12g, every twice-daily, be morning and evening (medicine) being taken before meal use, take 3 months as a course for the treatment of.
Below advantage or the principle of aforementioned techniques scheme are described:
1, the basic cause of disease of chronic viral hepatitis B is the positive deficiency of vital energy, damp and hotly takes advantage of empty invasion, causes for a long time kidney water and does not contain edema with the liver involved, the edema with the liver involved fire that do not nourish heart; Long-term damp and hot middle resistance, cause that the liver QI and blood is retarded by silt, Liver and kidney is two empty.Delaying the Therapeutic Principle of effecting a permanent cure according to the anxious table of controlling of the traditional Chinese medical science, it is main that the rule for the treatment of is answered strengthening vital QI to eliminate pathogenic factors, blood circulation promoting and blood stasis dispelling, depressed liver-energy dispersing and QI regulating, therefore take Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, Radix Astragali Preparata, the Cortex Eucommiae, Semen Cuscutae, Herba Patriniae, Rhizoma Coptidis as monarch drug, QI invigorating warming YANG and strengthening body resistance, clearing away damp-heat; The Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Poria, Rhizoma Alismatis, Semen Coicis are ministerial drug, clearing away phlegm damp eliminating (phlegm-damp easily stays heresy); Assistant is with, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Radix Salviae Miltiorrhizae, Flos Carthami, the broken what of Semen Persicae nourshing blood and promoting blood circulation, and with Radix Glycyrrhizae, Pericarpium Citri Reticulatae Viride, Radix Bupleuri, Fructus Citri Sarcodactylis and the circulation of qi promoting of medicine dispelling the stagnated QI, Carapax Trionycis (processed) nourishing YIN for suppressing the hyperactive YANG (not staying heat while making QI invigorating and body resistance strengthening) for the 20 pleasant impression medicine composition side medicines such as making, make pill and treated.
2, according to R﹠D of modern TCM, Herba Patriniae, Rhizoma Coptidis, Radix Glycyrrhizae all have the effect and the Herba Patriniae that suppress hepatitis B virus that the ability that promotes liver cell regeneration is arranged again; Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, Radix Astragali Preparata, Poria, Rhizoma Alismatis, Semen Coicis are improved the effect of body immunity; The Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Radix Salviae Miltiorrhizae, Flos Carthami, Semen Persicae have the blood vessel wall immune complex effect that is deposited on of removing; The Radix Paeoniae Alba, Radix Rehmanniae Preparata, Pericarpium Citri Reticulatae Viride, Radix Bupleuri, Fructus Citri Sarcodactylis, Carapax Trionycis (processed) have the effect of enriching blood and regulating function of nervous system.
3, the present invention has good effect, has no side effect, and can fundamentally treat chronic viral hepatitis B and hepatitis B virus carriers.
The specific embodiment
Below embodiments of the invention are elaborated:
a kind of Chinese medicine preparation for the treatment of the chronic viral hepatitis B disease, according to weight ratio, formed by following raw material: Herba Patriniae 15-20 part, Semen Coicis 15-20 part, Radix Ginseng 15-20 part, Rhizoma Atractylodis Macrocephalae 15-20 part, Radix Astragali Preparata 15-20 part, Cortex Eucommiae 15-20 part, Semen Cuscutae 20-30 part, Rhizoma Coptidis 2-3 part, Rhizoma Pinelliae Preparata 6-9 part, Pericarpium Citri Reticulatae 6-9 part, Radix Paeoniae Alba 15-20 part, Radix Rehmanniae Preparata 20-30 part, Radix Salviae Miltiorrhizae 9-10 part, Flos Carthami 9-10 part, Semen Persicae 9-10 part, Radix Glycyrrhizae 20-30 part, Pericarpium Citri Reticulatae Viride 9-10 part, Radix Bupleuri 15-20 part, Fructus Citri Sarcodactylis 10-15 part, Carapax Trionycis (processed) 20-30 part, Poria 9-12 part and Rhizoma Alismatis 6-9 part.
Above all medicines are taken according to quantity, oven dry, pulverizing, porphyrize post-treatment are made pill, then pill are treated to chronic hepatitis B and hepatitis B virus carriers, adopt oral method, each oral 12g, every twice-daily ((medicine) being taken before meal is used sooner or later), take take 3 months as a course for the treatment of.
Observe by the treatment to the 29 random patients of example, after taking pill 1-2 week of the present invention, weak, dizzy, detest oil, yellowish urine, uncomfortable liver area, the clinical symptoms such as sleep is not good enough, poor appetite, abdominal distention, loose stool and hepatic facies is eased, take 2-4 after week clinical symptoms substantially disappear, its total effective rate reaches more than 90%, and acomia incumbent what toxic and side effects produces.
And by laboratory biochemical analysis tracing observation such as following table 1 to 6 examples wherein, 3 months therapeutic effect:
Table 1
(annotate: assay method is: the measuring method of HBSAg, HbsAb is chemoluminescence method; The measuring method of pcr dna is the fluorescent quantitative method).
And from foregoing, can obtain as drawing a conclusion:
1, with Chinese medicine standard judgement curative effect, the 29 random patient's medication 1-2 of example week clinical symptoms are all improved, and after 4 weeks of medication, clinical symptoms disappears substantially, and is evident in efficacy.
2, with modern medicine laboratory biochemistry detection standard judgement curative effect, the 6 random patient's medications of example are all obviously decline of HbsAg, pcr dna in patient's five indexes of hepatitis b after 1 month, after medication 2-3 month, the decline of patient HbsAg, pcr dna detection index weakens, but HbsAb generation and the phenomenon that progressively increases have occurred, had in addition 2 routine patients to follow the tracks of 2 years HbsAg the moon for the treatment of observation and turn the pcr dna disappearance.
3, above therapeutic effect, prove that Chinese medicine preparation pill of the present invention can play the inhibition hepatitis B virus duplication, activates body immune system, promotes patient self to produce HbsAb HbsAg is carried out the effect that the oneself removes.Simultaneously along with the disappearance of clinical symptoms and the improvement of liver function, this Therapeutic Method has also played the effect of conditioning emotion, make patient's social mentality and quality of life be improved significantly.
The above embodiment has only expressed the specific embodiment of the present invention, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to the scope of the claims of the present invention.Should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.
Claims (2)
1. Chinese medicine preparation for the treatment of the chronic viral hepatitis B disease, it is characterized in that: according to weight ratio, formed by following raw material, Herba Patriniae: 4.5-10%, Semen Coicis: 4.5-10%, Radix Ginseng: 4.5-5%, the Rhizoma Atractylodis Macrocephalae: 4.5-5%, Radix Astragali Preparata: 4.5-5%, the Cortex Eucommiae: 4.5-5%, Semen Cuscutae: 9-10%, Rhizoma Coptidis: 1-2%, Rhizoma Pinelliae Preparata 2-3%, Pericarpium Citri Reticulatae: 2-3%, the Radix Paeoniae Alba: 5-6%, Radix Rehmanniae Preparata: 9-10%, Radix Salviae Miltiorrhizae: 2.8-3.1%, Flos Carthami: 2.8-3.1%, Semen Persicae: 2.8-3.1%, Radix Glycyrrhizae: 4-5%, Pericarpium Citri Reticulatae Viride: 2.8-3.1%, Radix Bupleuri: 6-6.5%, Fructus Citri Sarcodactylis: 4.5-5%, Carapax Trionycis (processed): 9-10%, Poria: 3-3.7%, Rhizoma Alismatis: 1.6-1.9%.
2. the Chinese medicine preparation for the treatment of chronic viral hepatitis B disease according to claim 1, is characterized in that: make the watered pill after porphyrize is pulverized in the above-mentioned raw materials oven dry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103343875A CN102813855B (en) | 2012-09-12 | 2012-09-12 | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012103343875A CN102813855B (en) | 2012-09-12 | 2012-09-12 | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102813855A CN102813855A (en) | 2012-12-12 |
| CN102813855B true CN102813855B (en) | 2013-11-13 |
Family
ID=47298537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103343875A Active CN102813855B (en) | 2012-09-12 | 2012-09-12 | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102813855B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142735B (en) * | 2013-03-09 | 2014-07-23 | 河北工程大学 | Traditional Chinese medicine oral liquid for treating duck virus hepatitis |
| CN105106842A (en) * | 2015-09-02 | 2015-12-02 | 江淑芬 | Medicine for treating chronic hepatitis B |
| CN105147819B (en) * | 2015-10-08 | 2018-11-09 | 广州市第八人民医院 | A kind of Radix Astragali pharmaceutical composition is preparing the purposes in treating hepatitis B medicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044974C (en) * | 1994-06-17 | 1999-09-08 | 殷广全 | Anti- hepatitis B preparation |
| CN1124153A (en) * | 1994-12-06 | 1996-06-12 | 蒋正文 | Medicine for recovery and replenishing liver and its preparing method |
| CN101695562B (en) * | 2009-11-05 | 2011-12-28 | 安徽丰原药业股份有限公司 | Chinese medicinal composition for treating viral hepatitis and preparation method thereof |
-
2012
- 2012-09-12 CN CN2012103343875A patent/CN102813855B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102813855A (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455078B1 (en) | Medicinal herbal composition for treating liver diseases and HIV | |
| CN102813855B (en) | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof | |
| CN104707108A (en) | Traditional Chinese medicine composition for treating chronic virulent hepatitis b and preparation method thereof | |
| CN102178788B (en) | Chinese medicinal composition for reducing transaminase and jaundice and preparation method thereof | |
| CN1329047C (en) | Chinese medicinal composition for treating acute icterohepatitis | |
| CN101342338B (en) | Medicament for treating hepatopathy | |
| CN101766720B (en) | Medicine for treatment of liver disease | |
| CN101357184A (en) | Chinese traditional medicine for treating hepatosis and preparation method thereof | |
| CN104116971B (en) | Traditional Chinese medicine composition for treating liver disease pruritus and preparation method thereof | |
| CN102949659B (en) | Traditional Chinese medicine composition for treating hepatitis B | |
| CN101940758B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and application thereof | |
| CN101461857B (en) | Medicament for treating severe hepatitis | |
| CN103007204B (en) | Chinese medicinal composition for treating hepatofibrosis | |
| CN106237263A (en) | A kind of treat acute icterohepatitis and Chinese medicine composition that chronic hepatitis acute onset raises with bilirubin | |
| CN111228388A (en) | A pharmaceutical composition for treating hepatopathy, and its application method | |
| CN103272183B (en) | Traditional Chinese medicine for treating hepatitis B induced cirrhosis | |
| CN104127602A (en) | Traditional Chinese medicine for treating fatty liver | |
| CN103611035A (en) | Traditional Chinese medicine composition for treating phlegm-dampness stagnation type fatty liver | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof | |
| CN101199821B (en) | Medicament for treating chronic enteritis | |
| CN100591353C (en) | Traditional Chinese medicine formulation for treating hepatitis and its preparation method | |
| CN102178789B (en) | Hepatitis B virus resistant traditional Chinese medicine composition and preparation method thereof | |
| CN101837049A (en) | Chinese composition and preparation method and application thereof | |
| Yan et al. | Investigation of therapeutic effect of Longchai Formula Granule on chronic hepatitis B patients: A double-blind, controlled and randomized clinical trial | |
| CN101607071B (en) | Medicine for treating chronic hepatitis B and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |